Long-Term Effects of Radioiodine Treatment on Salivary Gland Function in Adult Survivors of Pediatric Differentiated Thyroid Carcinoma

Autor: Selvakumar, T., Nies, M., Hesselink, M.S.K., Brouwers, A.H., Horst-Schrivers, A.N.A. van der, Hesselink, E.N.K., Tissing, W.J.E., Vissink, A., Links, T.P., Bocca, G., Burgerhof, J.G.M., Dam, E.W.C.M. van, Havekes, B., Heuvel-Eibrink, M.M. van den, Corssmit, E.P.M., Kremer, L.C.M., Netea-Maier, R.T., Pal, H.J.H. van der, Peeters, R.P., Smit, J.W.A., Plukker, J.T.M., Ronckers, C.M., Santen, H.M. van, Dutch Pediat Thyroid Canc Study Co
Přispěvatelé: Guided Treatment in Optimal Selected Cancer Patients (GUTS), Personalized Healthcare Technology (PHT), Translational Immunology Groningen (TRIGR), Damage and Repair in Cancer Development and Cancer Treatment (DARE), ​Basic and Translational Research and Imaging Methodology Development in Groningen (BRIDGE), Internal medicine, CCA - Cancer Treatment and quality of life, Amsterdam Reproduction & Development (AR&D), Internal Medicine, RS: NUTRIM - R1 - Obesity, diabetes and cardiovascular health, MUMC+: MA Endocrinologie (9), Interne Geneeskunde
Rok vydání: 2018
Předmět:
salivary gland dysfunction
medicine.medical_specialty
Saliva
FLOW
030209 endocrinology & metabolism
XEROSTOMIA
Rare cancers Radboud Institute for Molecular Life Sciences [Radboudumc 9]
Gastroenterology
Healthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18]
Thyroid carcinoma
03 medical and health sciences
All institutes and research themes of the Radboud University Medical Center
0302 clinical medicine
stomatognathic system
QUALITY-OF-LIFE
Internal medicine
medicine
FERTILITY
Endocrine system
Radiology
Nuclear Medicine and imaging
I-131 THERAPY
Thyroid cancer
RISK
radioiodine treatment
Salivary gland
business.industry
Cancer
pediatric differentiated thyroid carcinoma
RADIOACTIVE IODINE THERAPY
medicine.disease
CANCER
Sialadenitis
INTERMEDIATE
medicine.anatomical_structure
SIALADENITIS
Radiology Nuclear Medicine and imaging
030220 oncology & carcinogenesis
business
Rare disease
Zdroj: The Journal of Nuclear Medicine (1978), 60, 2, pp. 172-177
Journal of Nuclear Medicine, 60(2), 172-177. SOC NUCLEAR MEDICINE INC
Journal of Nuclear Medicine, 60(2), 172-177
The Journal of Nuclear Medicine (1978), 60, 172-177
Journal of Nuclear Medicine, 60(2), 172-177. Society of Nuclear Medicine Inc.
Journal of Nuclear Medicine, 60(2), 172-177. Society of Nuclear Medicine and Molecular Imaging
Selvakumar, T, Nies, M, Klein Hesselink, M S, Brouwers, A H, Van Der Horst-Schrivers, A N A, Klein Hesselink, E N, Tissing, W J E, Vissink, A, Links, T P & Dutch Pediatric Thyroid Cancer Study Consortium 2019, ' Long-term effects of radioiodine treatment on salivary gland function in adult survivors of pediatric differentiated thyroid carcinoma ', Journal of Nuclear Medicine, vol. 60, no. 2, pp. 172-177 . https://doi.org/10.2967/jnumed.118.212449
Journal of Nuclear Medicine, 60(2), 172. Society of Nuclear Medicine Inc.
ISSN: 2159-662X
0161-5505
Popis: Pediatric differentiated thyroid cancer (DTC) is a rare disease. Initial treatment of DTC consists of a total or near-total thyroidectomy and 131 I therapy. Previous studies on adults showed that 131 I treatment may reduce salivary gland function (SGF). Studies regarding SGF in children treated for DTC are sparse. Our aim was to assess the long-term effects of 131 I treatment on SGF in survivors of pediatric DTC. Methods: In a nationwide cross-sectional study, SGF in patients treated for pediatric DTC between 1970 and 2013 (.5 y after diagnosis, $18 y old at the time of evaluation) was studied. SGF was assessed by sialometry, sialochemistry, and a xerostomia inventory. Salivary gland dysfunction (SGD) was defined as an unstimulated whole saliva flow of no more than 0.2 mL/min or a stimulated whole saliva flow of no more than 0.7 mL/min. Results: Sixty-five patients underwent 131 I treatment (median age at evaluation, 33 y, with an interquartile range [IQR] of 25–40 y; 86.2% female; median follow-up period, 11 y, with an IQR of 6–22 y). Median cumulative 131 I activity was 5.88 GBq, with an IQR of 2.92–12.95 GBq, and 47.7% underwent multiple 131 I administrations. SGD was present in 30 (47.6%) patients. Levels of amylase and total protein in saliva were reduced. Moderate to severe xerostomia was present in 22 (35.5%) patients. Stimulated salivary secretion was lower and the severity of xerostomia complaints higher in patients treated with higher cumulative 131 I activity. Conclusion: In survivors of pediatric DTC, clinically significant SGD was found in 35.5% and was related to the cumulative 131 I activity of the treatment.
Databáze: OpenAIRE
Externí odkaz: